- Home
- ITRM vs PYPD Comparison
ITRM vs PYPD Comparison
Compare ITRM & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- PYPD
- Stock Information
- Founded
- ITRM 2015
- PYPD 2008
- Country
- ITRM Ireland
- PYPD Israel
- Employees
- ITRM N/A
- PYPD N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- ITRM Health Care
- PYPD Health Care
- Exchange
- ITRM Nasdaq
- PYPD Nasdaq
- Market Cap
- ITRM 40.0M
- PYPD 34.8M
- IPO Year
- ITRM 2018
- PYPD 2020
- Fundamental
- Price
- ITRM $0.68
- PYPD $3.47
- Analyst Decision
- ITRM Strong Buy
- PYPD Strong Buy
- Analyst Count
- ITRM 2
- PYPD 5
- Target Price
- ITRM $7.00
- PYPD $12.00
- AVG Volume (30 Days)
- ITRM 749.8K
- PYPD 58.1K
- Earning Date
- ITRM 11-13-2025
- PYPD 11-12-2025
- Dividend Yield
- ITRM N/A
- PYPD N/A
- EPS Growth
- ITRM N/A
- PYPD N/A
- EPS
- ITRM N/A
- PYPD N/A
- Revenue
- ITRM N/A
- PYPD N/A
- Revenue This Year
- ITRM N/A
- PYPD N/A
- Revenue Next Year
- ITRM $249.35
- PYPD N/A
- P/E Ratio
- ITRM N/A
- PYPD N/A
- Revenue Growth
- ITRM N/A
- PYPD N/A
- 52 Week Low
- ITRM $0.61
- PYPD $2.30
- 52 Week High
- ITRM $3.02
- PYPD $3.93
- Technical
- Relative Strength Index (RSI)
- ITRM 43.17
- PYPD 52.65
- Support Level
- ITRM $0.61
- PYPD $3.42
- Resistance Level
- ITRM $0.76
- PYPD $3.53
- Average True Range (ATR)
- ITRM 0.05
- PYPD 0.11
- MACD
- ITRM 0.01
- PYPD 0.01
- Stochastic Oscillator
- ITRM 49.65
- PYPD 68.56
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.